다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

IMTX

Immatics NV (IMTX)

Immatics NV

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IMTX

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/14	20:00	GlobeNewswire Inc.	Immatics Announces First Quarter 2024 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2024/03/21	20:00	GlobeNewswire Inc.	Immatics Announces Full Year 2023 Financial Results and Corporate Update	NASDAQ:IMTX	Immatics NV
2024/01/23	02:52	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2024/01/19	22:58	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMTX	Immatics NV
2024/01/18	10:30	GlobeNewswire Inc.	Immatics Announces Pricing of $175 Million Public Offering	NASDAQ:IMTX	Immatics NV
2024/01/18	06:11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMTX	Immatics NV
2024/01/18	06:01	GlobeNewswire Inc.	Immatics Announces Proposed Public Offering	NASDAQ:IMTX	Immatics NV
2024/01/16	18:06	PR Newswire (US)	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing	NASDAQ:IMTX	Immatics NV
2024/01/16	17:59	PR Newswire (US)	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing	NASDAQ:IMTX	Immatics NV
2023/11/30	18:00	GlobeNewswire Inc.	Levicept Appoints Eliot Forster as CEO	NASDAQ:IMTX	Immatics NV
2023/11/14	21:00	GlobeNewswire Inc.	Immatics Announces Third Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/11/08	21:30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/11/08	21:00	GlobeNewswire Inc.	Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	NASDAQ:IMTX	Immatics NV
2023/10/24	20:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/10/24	20:00	GlobeNewswire Inc.	Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy	NASDAQ:IMTX	Immatics NV
2023/09/14	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IMTX	Immatics NV
2023/09/14	06:03	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:IMTX	Immatics NV
2023/09/11	20:00	GlobeNewswire Inc.	Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics	NASDAQ:IMTX	Immatics NV
2023/09/11	19:33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/26	05:11	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:IMTX	Immatics NV
2023/08/17	20:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/17	20:00	GlobeNewswire Inc.	Immatics Announces Second Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/08/10	20:08	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/08/10	20:00	GlobeNewswire Inc.	Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors	NASDAQ:IMTX	Immatics NV
2023/07/24	20:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMTX	Immatics NV
2023/07/24	20:00	GlobeNewswire Inc.	Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb	NASDAQ:IMTX	Immatics NV
2023/06/21	05:21	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IMTX	Immatics NV
2023/05/16	20:06	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:IMTX	Immatics NV
2023/05/16	20:00	GlobeNewswire Inc.	Immatics Announces First Quarter 2023 Financial Results and Business Update	NASDAQ:IMTX	Immatics NV
2023/05/02	20:00	GlobeNewswire Inc.	Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME	NASDAQ:IMTX	Immatics NV

검색 관련기사 보기:NASDAQ:IMTX

1 2 3 4 5 다음 >>

Proshares Ultrashort Bit...

Maternus Kliniken

NLBNPIT21JP8 20240620 5500

Intsanpaolo Sc Nv27 Usd

CryptoInsight TKRToken

Real Asset NFT Plus

ITUBU326 Ex:31,21

SP Funds S&P Global Reit...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관